Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,291,785 papers from all fields of science
Search
Sign In
Create Free Account
DX 8951f
Known as:
DX-8951f
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (2)
exatecan
exatecan mesylate
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2004
Highly Cited
2004
A randomized phase III trial of DX-8951f (Exatecan Mesylate; DX) and Gemcitabine (GEM) vs. Gemcitabine alone in advanced pancreatic cancer (APC).
E. M. O 'reilly
,
G. Abou-Alfa
,
+7 authors
S. Eckhardt
Journal of Clinical Oncology
2004
Corpus ID: 21906610
4006 BACKGROUND: DX is a novel hexacyclic, water-soluble, topoisomerase-1 inhibitor. DX has single-agent and combination activity…
Expand
2004
2004
A Phase II Study of Intravenous Exatecan Mesylate (DX-8951f) Administered Daily for Five Days Every Three Weeks to Patients with Metastatic Adenocarcinoma of the Colon or Rectum
M. Royce
,
E. Rowinsky
,
+4 authors
L. Saltz
Investigational new drugs
2004
Corpus ID: 23061394
Background: To evaluate the antitumor activity, toxicities, and pharmacokinetics (PK) of DX-8951f administered as a 30-min…
Expand
2004
2004
Pharmacokinetics of DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f, in tumor-bearing mice.
N. Masubuchi
Pharmazie
2004
Corpus ID: 25866811
To improve the distribution of the novel camptothecin analog DX-8951, DE-310, which is composed of DX-8951 covalently linked to a…
Expand
2003
2003
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane…
C. Verschraegen
,
A. Kudelka
,
+6 authors
R. Jager
Cancer Chemotherapy and Pharmacology
2003
Corpus ID: 29006454
BackgroundDX-8951f is a water-soluble camptothecin derivative with greater in vivo and in vitro activity than topotecan or…
Expand
2003
2003
Phase I and pharmacological study of oral 9-aminocamptothecin colloidal dispersion (NSC 603071) in patients with advanced solid tumors.
H. Xiong
,
H. Tran
,
T. Madden
,
R. Newman
,
J. Abbruzzese
Clinical Cancer Research
2003
Corpus ID: 799170
PURPOSE 9-Aminocamptothecin colloidal dispersion (9-ACCD; NSC 603071) is a specific inhibitor of topoisomerase I that can be…
Expand
2002
2002
Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: Determination of efficacy and possible mechanisms of resistance
A. H. van Hattum
,
H. M. Schlüper
,
Frederick H Hausheer
,
H. Pinedo
,
E. Boven
International Journal of Cancer
2002
Corpus ID: 11327378
The novel camptothecin derivative BNP1350 (7‐[2‐trimethylsilyl)ethyl]‐20(S)‐camptothecin), also known as Karenitecin, has been…
Expand
2000
2000
Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer.
V. Boige
,
E. Raymond
,
+7 authors
J. Armand
Journal of Clinical Oncology
2000
Corpus ID: 13534175
PURPOSE DX-8951f is a totally synthetic derivative of camptothecin with greater cytotoxicity and more potent topoisomerase I…
Expand
2000
2000
Phase II Study of Intravenous DX‐8951f in Patients with Advanced Ovarian, Tubal, or Peritoneal Cancer Refractory to Platinum, Taxane, and Topotecan
C. Verschraegen
,
C. Levenback
,
+5 authors
J. Kavanagh
Annals of the New York Academy of Sciences
2000
Corpus ID: 35365822
In phase I studies of DX-8951f, anti-tumor activity (including partial remissions) was documented with the daily × 5 and the…
Expand
Review
1999
Review
1999
Topoisomerase I inhibitors in the treatment of colorectal cancer.
M. Rothenberg
,
C. Blanke
Seminars in Oncology
1999
Corpus ID: 37197191
Over the past 10 years, a number of topoisomerase I inhibitors have entered into clinical trials and several of these have been…
Expand
1998
1998
Characterization of a Human Small‐cell Lung Cancer Cell Line Resistant to a New Water‐soluble Camptothecin Derivative, DX‐8951f
T. Nomoto
,
K. Nishio
,
T. Ishida
,
M. Mori
,
N. Saijo
Japanese journal of cancer research : Gann
1998
Corpus ID: 13723468
DX‐8951f, a water‐soluble and non‐pro‐drug analogue of camptothecin, exhibits a strong inhibitory action on DNA topoisomerase I…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE